By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Cepheid today announced a partnership with Novartis to commercialize a molecular diagnostic test for Philadelphia chromosome-positive chronic myelogenous leukemia, or Ph+CML.

The Xpert BCR-ABL test is based on Cepheid's GeneXpert system. It is CE marked and has been available for sale outside the US since 2006. The deal announced today would accelerate efforts to get clearance from the US Food and Drug Administration for commercial launch in the US of the test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: Leukemia-like disease in soft-shell clams, mNET-seq method for profiling growing transcripts, and more.

While James Watson and Francis Crick are credited for discovering the structure of DNA, Rich proved their theory of a double helix structure was correct when he produced a distinct image of the structure.

Nature News reports that early users of Oxford Nanopore's hand-held MinIon are giddy about the technology and its uses. 

According to MIT Technology Review, Apple is collaborating with researchers to develop apps for consumer DNA testing.